XPO1抑制药在血液肿瘤治疗中的研究现状  

Research status of XPO1 inhibitors in the treatment of hematological tumors

作　　者：张莹[1] 蔡真[2] ZHANG Ying;CAI Zhen(Department of Blood Transfusion,Lishui Hospital of Zhejiang University,Lishui 323000,Zhejiang Province,China;Bone Marrow Transplantation Center,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,Zhejiang Province,China)

机构地区：[1]浙江大学丽水医院输血科,浙江丽水323000 [2]浙江大学医学院附属第一医院骨髓移植中心,浙江杭州310003

出　　处：《中国临床药理学杂志》2024年第23期3487-3491,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：核输出蛋白1(XPO1)抑制药通过抑制重要蛋白质和RNA的核输出在血液肿瘤治疗上发挥优势。XPO1抑制药可以与多种药物产生协同作用,增加对伙伴药物和方案的敏感性,成为多药耐药、复发难治血液肿瘤患者的有效选择,也是血液肿瘤治疗的新兴研究方向。本文总结了XPO1抑制药联合不同药物在血液肿瘤应用的基础研究机制,以及代表药物塞利尼索和Eltanexor在血液肿瘤临床研究的最新进展,为血液肿瘤治疗提供新的方案思路和用药指导。Exportin 1(XPO1)inhibitors exert the advantages in the treatment of hematological tumors by inhibiting the nuclear export of important proteins and RNAs.XPO1 inhibitors can produce synergistic effects with a variety of drugs and increase sensitivity to partner drugs and regimens,making them an effective choice for patients with multidrug resistance and relapsed and refractory hematological tumors.They are also an emerging research direction in the treatment of hematological tumors.This article summarizes the mechanism of XPO1 inhibitors combined with different drugs and the latest clinical progress in research of representative drugs Selinexor and Eltanexor in hematological tumors,providing new ideas of regimen and medication guidance for the treatment of hematological tumors.

关 键 词：核输出蛋白1抑制药 塞利尼索 Eltanexor 血液肿瘤 

分 类 号：R979.1[医药卫生—药品]